Precision BioSearch secures CEO for Oxford spin-out, Dark Blue Therapeutics, backed by OSE, BMS and Evotec
Precision BioSearch partnered with Dark Blue Therapeutics, a biotech company developing a pipeline of oncology programs from the University of Oxford and therapeutics accelerator LAB282. Dark Blue leverages ground-breaking cancer biology insights to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. Precision BioSearch is pleased to secure the appointment of Dr Alastair MacKinnon as Chief Executive Officer.
Alastair is a veteran Biotech Executive equipped with a breadth of industry knowledge gained through 25 years’ experience spanning medicine, biotech investing, company creation and building. He is a qualified Medical Doctor and practiced cardiovascular and oncology surgery before joining Phase4 Ventures, a VC firm. He subsequently co-founded Mereo Biopharma through the acquisition of assets from Novartis and AstraZeneca and was involved in multiple major financing rounds, totalling over $300M.
Commenting on his appointment, Alastair MacKinnon, CEO, said:
“Dark Blue have developed a unique relationship with the University of Oxford and LAB282. This has become a platform enabling rapid drug discovery to novel targets. It’s an exciting time to be joining Dark Blue, who have developed a pipeline of first in class oncology programs, each with clinical line of sight as single agent, precision medicines. I am particularly impressed by the rapid progress the Dark Blue team has made across the pipeline and look forward to delivering on this foundation .”
About Dark Blue Therapeutics: Dark Blue Therapeutics is an innovative cancer drug discovery company leveraging ground-breaking therapeutic and disease insights to exploit cancer’s vulnerabilities and dependencies. Dark Blue have assembled a team of passionate, seasoned industry experts with backgrounds that span the breadth of innovative drug development from discovery to approval. The team includes innovators and senior leaders from biotech, large pharmaceutical companies and investment management. With deep, proprietary understanding of target biology they match their precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs, delivering medicines that transform the outcomes for cancer patients.
For more information, visit:
The team will also be attending AACR and ASCO 2023.
Posted on : 11th April 2023